

CSD/BSE&NSE/BM/2026-27

April 27, 2026

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”), we hereby inform that the Board of Directors of the Company at its meeting held today i.e., April 27, 2026 inter-alia considered and approved the following:

1. Taking note of the resignation of the Executive Chairman and Director: The Board of Directors of the Company has noted the resignation of Mr. Vivek Sharma (DIN 08559495), as Executive Chairman and director of the Company. In view of his resignation, he will cease to be the Executive Chairman and director with effect from the close of business hours of 30 April 2026. However, he will continue to provide his services to the Company in the role of Special Advisor to the Company to help transition the business effectively and drive continuity over the next 9 (nine) months.

The Board placed on record its appreciation for the valuable contribution made by Mr. Sharma during his tenure on the Board.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 on the captioned subject and the resignation letter dated April 26, 2026 along with reasons for the resignation, as received from Mr. Sharma, are set out in Annexure – A.

2. Appointment of Mr. Umang Vohra as Additional Director, designated as Chairman, and Group Chief Executive Officer: The Board of Directors of the Company, based on the recommendation of the nomination and remuneration committee at its meeting held on April 26, 2026, approved the appointment of Mr. Umang Vohra (DIN: 02296740) as Additional Director, for a period of 5 (five) years from the opening business hours of 1 May 2026 to 30 April 2031, not liable to retire by rotation,

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road,
Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



designated as Chairman, with effect from the opening business hours of 1 May 2026, and as Group Chief Executive Officer of the Company, from the opening business hours of 20 May 2026, in each case, till 30 April 2031 and subject to the approval of the shareholders of the Company and of the statutory and regulatory authorities as applicable.

The brief profile of Mr. Vohra is annexed with this disclosure.

Mr. Vohra is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 on the captioned subject are set out in Annexure – B.

3. Approval of Cohance Lifesciences Limited – Employee Stock Option Plan, 2026: The Board of Directors of the Company based on the recommendation of the nomination and remuneration committee at its meeting held on April 26, 2026, approved the adoption of the Cohance Lifesciences Limited – Employee Stock Option Plan, 2026, in accordance with Securities and Exchange Board of India (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, subject to approval of the shareholders of the Company.

The details required to be disclosed under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 on the captioned subject are set out in Annexure – C.

4. Approval of the notice of postal ballot seeking approval of shareholders of the Company for the matters mentioned at Sl No. 2 and 3 above and other matters connected to postal ballot.

The Board Meeting commenced at 7:00 am IST and concluded at 7:50 am IST.

This is for your information and record.

Thanking you,

Yours faithfully,

For **Cohance Lifesciences Limited**

Sisir K. Mishra
Company Secretary & Compliance Officer
Encl: as above



Annexure – A

Disclosure of information pursuant to Regulation 30 of the SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

1	Name of Person	Mr. Vivek Sharma
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation of Mr. Vivek Sharma as Executive Chairman and director, and his redesignation as the Special Advisor to the Company. The resignation letter received from Mr. Vivek Sharma is annexed herewith.
3	Date of appointment / re-appointment / cessation (as applicable) and term of appointment / re-appointment	30 April 2026
4	Brief profile (in case of appointment)	Not applicable
5	Disclosure of relationship between directors (in case of appointment of a director)	Not applicable

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Annexure – B

1	Name of Person	Mr. Umang Vohra
2	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Umang Vohra as: Additional Director, designated as Chairman and Group Chief Executive Officer of the Company, subject to the approval of the shareholders of the Company.
3	Date of appointment / re-appointment / cessation (as applicable) and term of appointment / re-appointment	<u>Director</u> : Opening business hours of 1 May 2026. <u>Group Chief Executive Officer</u> : Opening business hours of 20 May 2026. <u>Term of appointment</u> : 5 years from 1 May 2026 till 30 April 2031.
4	Brief profile (in case of appointment)	Enclosed.
5	Disclosure of relationship between directors (in case of appointment of a director)	Mr. Umang Vohra is not related to any of the Directors or Key Managerial Personnel of the Company and is not debarred from holding the office of Director by virtue of any SEBI order or any other such authority.

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Annexure – C

Sr No	Particulars	Remarks
1	Brief details of Options granted	25,918,613 employee stock options (“ Options ”), which may be offered and granted in one or more tranches, each convertible into one equity share of the Company of face value of INR 1/- each (or such other adjusted figure for any bonus, stock splits, buy-back, scheme of arrangement or consolidations or other reorganization of the capital structure of the Company as may be applicable from time to time), which represents 6.25% of the fully diluted equity share capital assuming all such Options are exercised.
2	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable)	Yes
3	Total number of shares covered by these options	<p>The total number of Options which may be offered and granted are 25,918,613 Options. Each Option is convertible into one equity share of the Company of face value of INR 1/- each (or such other adjusted figure for any bonus, stock splits, buy-back, scheme of arrangement or consolidations or other reorganization of the capital structure of the Company as may be applicable from time to time), which represents 6.25% of the fully diluted equity share capital assuming all such Options are exercised.</p> <p>The Company shall restrict the outstanding grants under the existing Cohance Lifesciences Limited Stock Option Plan 2023 (the “ESOP 2023”), and as of 31 December 2026, the grants under the ESOP 2023 shall aggregate to not more than 1.5% of the Company’s share capital on a fully diluted basis. On an aggregate basis, the total dilution on account of the stock options under ESOP 2023 and the Cohance Lifesciences Limited – Employee Stock Option Plan, 2026 over a period of 7.5 (seven and a half) years, is expected to be not more than 7.75% on a fully diluted basis, which translates into ~1% dilution on an annual basis.</p>
4	Pricing formula	The exercise price per option shall be decided by the Board/ Nomination and Remuneration Committee at its sole discretion as on the date of grant but shall not be less than INR 325 per share

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



		<p>(which is a 2.5% discount to the average market price of the shares of the Company over the last 21 (twenty-one) trading days prior to the approval of ESOP 2026 by the Board on 27 April 2026) as on date of grant of such Option for any grant that is made within 6 months of the date of receipt of in-principle approval from the stock exchange following the approval of the shareholders.</p> <p>In the case of any grant made after such period, the exercise price shall not be at more than a 20% discount to the average market price of the shares of the Company over a 21 (twenty-one) trading days' period preceding one trading day prior to the date of such grant. The specific exercise price shall be intimated to the participant in the grant letter at the time of grant. No exercise price to be paid at the time of grant or vesting of Option by the participant.</p>
5	Options vested	Nil
6	Time within which option may be exercised	The exercise period shall be up to 3 years from the date of vesting of options.
7	Options exercised	Nil
8	Money realized by exercise of options	Nil
9	The total number of shares arising as a result of exercise of option	Nil
10	Options lapsed	Nil
11	Variation of terms of options	Not applicable
12	Brief details of significant terms	Options granted under the plan shall vest not earlier than minimum period of 1 year and not later than maximum period of 8 years from the date of grant.
13	Subsequent changes or cancellation or exercise of such options	Not applicable
14	Diluted earnings per share pursuant to issue of equity shares on exercise of options	Not applicable

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com



Dated: 25/04/2026

To:

Cohance Lifesciences Limited
215 Atrium, C Wing, 5th Floor, 819-821,
Andheri Kurla Road, Chakala, Andheri East,
Chakala Side, Mumbai- 400093,
Maharashtra, India

Attention: The Board of Directors

Sub: Resignation from the board of directors of Cohance Lifesciences Limited


I, Vivek Sharma (DIN: 08559495), hereby tender my resignation as Executive Chairman and Director of Cohance Life Sciences Limited, as well as from all Board Committees of which I am a member or Chair, with effect from the closing of business hours on April 30, 2026, due to personal reasons.

It has been a privilege to serve the Company during this important phase of its journey. I deeply value the opportunity to have worked alongside a distinguished Board and a committed management team, and to have contributed to shaping the Company's strategic direction and governance framework. I am especially grateful to our employees for their dedication and commitment, and to our customers for their trust and partnership, both of which have been central to the Company's long-term growth and purpose.

I remain confident in the Company's future and the strength of its leadership, and I wish the Board, management, employees, and our customers continued success in all their endeavours.

Thank you once again for the opportunity to serve.

Yours sincerely,


Vivek Sharma
DIN: 08559495